Clinical trial sponsors should consider the potential for missing data and bias when deciding whether to switch from in-person to remote collection of observer-reported and patient-reported outcome assessments during the COVID-19 pandemic, the US Food and Drug Administration says.
In the latest update to its question-and-answer guidance on managing the novel coronavirus’ impact on clinical trials, the agency...